case_images: PMC11763907_01
case_images: Prior to commencement of adalimumab. Extensive erythema and erosions over torso. PDAI: Activity 22, Damage 8. PDAI, Pemphigus Disease Area Index.
case_images: gr1.jpg
case_images: PMC11763907_01_gr1.jpg
case_images: fig1
case_images: After approximately 12 weeks of 40 mg of adalimumab every 2 weeks, our patient reported significant symptomatic improvement which is illustrated in Figures 1 and 2 below.
case_images: Significant improvement after 12 weeks of treatment with adalimumab. Postinflammatory erythema with scattered active erosions over abdomen. PDAI: Activity 7, Damage 6. PDAI, Pemphigus Disease Area Index.
case_images: gr2.jpg
case_images: PMC11763907_01_gr2.jpg
case_images: fig2
case_images: After approximately 12 weeks of 40 mg of adalimumab every 2 weeks, our patient reported significant symptomatic improvement which is illustrated in Figures 1 and 2 below.
case_images: Change in PDAI after commencement of adalimumab. PDAI, Pemphigus Disease Area Index.
case_images: gr3.jpg
case_images: PMC11763907_01_gr3.jpg
case_images: fig3
case_images: There was also an improvement in her PDAI activity and damage scores, as demonstrated in Figure 3.